Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Impact of previous BCMA exposure: Evidence from practice outside of clinical trials to inform talquetamab sequencing

View Full Paper
Ask AI
Bookmark
Share

Authors

ACAna Saus CarreresMAMario ArnaoEPElena Fernández Poveda

Discussion

Loading...

Member takes

Overview

Observational analysis shows overall response rates of 89% for BCMA-exposed patients, indicating talquetamab's potential in multiple myeloma treatment.

Key Points

  • Overall response rates were 89% for BCMA exposed patients compared to 81% for BCMA naïve patients.
  • The median progression-free survival was 9.9 months in the BCMA exposed group and 8.4 months in the naïve group.
  • Chimeric antigen receptor T cells and antibody-drug conjugates were utilized in the treatment of patients.
  • The findings may assist in clinical decision-making for multiple myeloma treatment sequencing.

Cite This Study

Carreres et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df43https://doi.org/10.1182/blood-2025-2272
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Talquetamab outcomes from practice outside of clinical trials: The bital study2025
  2. 2Identifying high-risk profiles and adverse prognoses in relapsed/refractory multiple myeloma treated with bispecific antibodies: A real-world analysis of 943 treatment initiations2025
  3. 3Sequential BCMA- and GPRC5D-targeted bispecific antibody therapy in multiple myeloma: Real-world outcomes and first report of dual bispecific antibody-refractory patients2025
  4. 4Real‐World Treatment Patterns and Clinical Outcomes Among Patients With Triple‐Class–Exposed and BCMA‐Exposed Multiple Myeloma Within the United States2025 · 4 citations
  5. 5Talquetamab induces deep responses in heavily pre-treated patients with systemic light-chain amyloidosis2025